Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4Genitourinary 2Gastrointestinal 2Thoracic 1Sarcoma 1Head & Neck 1Dermatologic 1CNS 1Breast 1

Conditions

Breast Neoplasms 8Brain Neoplasms 8Neoplasm Metastasis 4Meningeal Carcinomatosis 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Astrocytoma 1

Interventions

Filgrastim 12Carboplatin 10Paclitaxel 9Peripheral Blood Stem Cell Transplantation 7Cyclophosphamide 7Ifosfamide 6Temozolomide 5Cisplatin 5pembrolizumab 4Nivolumab 4Gemcitabine 4Etoposide 4Docetaxel 4fludarabine 3Thiotepa 3Specimen Handling 3Psychiatric Rehabilitation 3Melphalan 3Magnetic Resonance Spectroscopy 3Immunologic Techniques 3Fluorodeoxyglucose F18 3Flow Cytometry 3Bevacizumab 3Amifostine 3ulixertinib 2trametinib 2sargramostim 2sapanisertib 2pegfilgrastim 2ixabepilone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × trastuzumab deruxtecan × CNS × Clear all
NCT05417594 2026-06-02

CERTIS1

AstraZeneca

Phase 1/2 Recruiting
695 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologic

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡